[Situation of translational research and development of molecular-targeted agents for multiple myeloma].
The most important point of the translational research for oncology is clinical application. The excellent research will clarify the molecular pathogenesis of cancer and develop a beneficial intervention in the clinic. The laboratory science done on patient material is a critical part of the translational research. However, there are several problems to expand the translational research in Japan. Developing excellent basic researches and arranging systems to support the translational research will be necessary.
Kizaki
Masahiro
M
Division of Hematology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D035843:Biomedical Research; D001897:Boronic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D000069286:Bortezomib; D015815:Cell Adhesion Molecules / Q000502:physiology; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000502:physiology; D015195:Drug Design; D018390:Gene Targeting; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics*; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011719:Pyrazines / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D015815:Cell Adhesion Molecules; D016207:Cytokines; D016328:NF-kappa B; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib